Should Platform Biotech Companies Partner, Sell, Or License Their Technology?

Platform technologies are celebrated for their potential to generate entire pipelines, yet many biotech companies struggle with how best to commercialize them. This article explores the strategic crossroads facing platform‑based organizations as they balance technology monetization with internal drug development.

Examine why selling technology requires a fundamentally different skill set than building drugs—and why many partnerships fail to deliver meaningful financial value beyond short‑term research funding. It also questions whether repeated platform collaborations unintentionally turn biotech innovators into service providers, creating operational strain and strategic distraction.

An alternative model is explored: separating platform commercialization from therapeutic development through licensing to partners with established sales infrastructure and scalable operations. While not without trade‑offs, this approach can unlock broader adoption while preserving internal focus.